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RXR motifSAP97 is directly involved in exporting NMDA receptors with a speciﬁc subunit composition from the endoplasmic
reticulum (ER). Characterization of the interactions between SAP97 and anNMDA receptor splice variant, GluN1-3,
and of the effects on forward trafﬁcking revealed that an ER-level interaction blocked the RXRER-retentionmotif in
the GluN1-3 cytoplasmic C-terminus in the context of both reportermolecules and full-length receptors. Binding of
SAP97 to the PDZ-binding domain of GluN1-3was required, but the blockade of ER-retentionwasmediated by the
SH3–GuK domains coupled with the action of the N-terminus of SAP97. While other domains of SAP97 were
involved in forward trafﬁcking of GluN1-3 out of the ER, the SH3 domain was necessary and sufﬁcient to block
the ER retention. This is the ﬁrst direct evidence for the masking of ER-retention signals by PDZ domain-
containing proteins, and provides detailed underlying mechanistic requirements. Such a mechanism could be
central to modulating the ER exit of receptors into local, non-conventional or conventional, secretory pathways
in neurons.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Glutamate receptor trafﬁcking modulates the strength of excitatory
synaptic responses. For example, induction of long-term potentiation
(LTP) by activation of NMDA receptors results in increased number of
AMPA receptors at potentiated synapses. Evidence indicates that
AMPA receptors are rapidly drawn from the extrasynaptic plasmamem-
brane [4], an endocytic receptor pool [27], and from the secretory path-
way [2,9]. Synaptic activity and experience are also directly involved in
NMDA receptor trafﬁcking events. Synaptic activity can switch synaptic
NMDA receptor subunit composition from GluN2B subunit-containing
to GluN2A subunit-containing receptors [1,28], which alters the require-
ments for induction of synaptic plasticity. Global inactivity has conse-
quences for NMDA receptor subunit composition as well. Blockade of
NMDA receptor activity transforms NMDA receptor subunit composi-
tion, and results in a change in the splicing of the GluN1 subunit
mRNA. This change transforms the C-terminus of GluN1 from predomi-
nantly the C2 splice cassette, which comprises the GluN1-1 andGluN1-2
forms, to one called C2′, which comprises the GluN1-3 and GluN1-4
forms. C2 and C2′ are alternative reading-frames of the same exon. The
transformation coincides with a redistribution of receptors, which
enhancesNMDA receptor targeting topostsynaptic sites [23,30]; however
the mechanisms that underlie the re-targeting are not well understood.iate compartment
.If the activity of synaptic NMDA receptors can determine what they
are ultimately replaced with, and if this can occur, in some cases, in a
dendritic sub-compartment-speciﬁc manner, then a unique feature of
these switches in receptor subunit composition has to be the linkage
of activity at particular synapses or sub-compartments of dendrites
with the de novo synthesis, transport, and targeting of nascent NMDA
receptors, which represents a difﬁcult sorting problem. An attractive
means of solving this sorting problemwould be the existence of synap-
tic signal-linked, local secretory pathways. To some extent, this kind of
pathway has already been observed. NMDA receptors comprised of
the GluN1-1 form trafﬁc primarily through a non-conventional secreto-
ry pathway,which bypasses the perinuclear Golgi, and traverses periph-
eral Golgi outposts [15]. Sorting of the bulk of NMDA receptors out of
the endoplasmic reticulum (ER) into this alternative local secretory
pathway was dependent on βSAP97 and CASK. The N-terminus of
SAP97 can be alternatively spliced to contain a double-cysteine/
palmitoylation site (α-isoform), or an L27 domain (β-isoform). The
L27 domain is involved in SAP97oligomerizationwith other SAP97mol-
ecules, CASK, and other L27-domain-containing proteins. Hereafter, all
references to SAP97 are to the β form of SAP97. Sequestration of
NMDA receptors in the ER can be relieved by CASK, so it appears that
both SAP97 and CASK participate in linking ER-associated nascent
NMDA receptors with the local secretory pathway. SAP97 has also
been shown to inhibit surface and synaptic delivery of other binding
partners, such as NMDA receptors, AMPA receptors, and Kir2 channels
[17], raising the possibility that SAP97 is a key regulator of the secretion
of its interacting partners at the ER level. In this study, another splice
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forms of GluN1 (GluN1-3 and GluN1-4) are up-regulated by alternative
splicing following NMDA receptor blockade [23,29]. Under such condi-
tions, there is no longer local synapse- or compartment-speciﬁc
NMDA receptor activity, and the swapping of existing NMDA receptor
forms for GluN1-3/4-containing forms could occur by default transport
through the conventional secretory pathway.
GluN1-3 has an ER retention signal, a PDZ-binding domain [33,37,
40], and a di-valine ER-exit motif nested in the PDZ-binding domain
[23]. While there is an agreement that the extreme C-terminus blocks
the ER retention motif, the mechanism has been unclear. Two hypothe-
ses have been proposed to explain the role of the C-terminus in
suppressing the ER-retention motif: 1) A PDZ–protein interaction with
the PDZ-binding domain of GluN1-3 that suppresses ER-retention [37],
or 2) an embedded di-valine motif present in the PDZ-binding domain
of GluN1-3 that acts as a dominant exit-signal motif, abrogating
ER-retention [23]. Both interpretations rely on indirect evidence. The
di-valine motif has not been directly demonstrated to dominate the ER
retention motif, and until now, no PDZ domain-containing protein has
been directly demonstrated to block ER retention. The reliance on indi-
rect evidence has been due in large part to the experimental difﬁculties
that the GluN1-3 full-length receptor presents. It is difﬁcult to assess the
rate of ER exit at a steady-state because, i) GluN1-3 is predominantly ER-
localized, but about 30% can be found on the cell surface in heterologous
cell lines when transfected alone [33,37]; ii) its asparagine-linked glyco-
sylation sites are not converted to a complex form [14]; iii) its
PDZ-binding domain associates with many PDZ proteins; iv) different
PDZ proteins may be associated with it at different locations along the
secretory pathway [36]; and v) PDZ proteins can have other effects
that confound interpretation, such as stabilizing receptors on the cell
surface [31]. In this study, we sought to determine if a PDZ protein
blocked the ER retention of GluN1-3, and if so, how blocking of ER reten-
tion was accomplished mechanistically. It is further speculated that the
identiﬁed mechanism represents one alternative of a binary sorting
decision made by ER-localized SAP97.
2. Results
To analyze the effects of PDZ proteins on the ER retention of GluN1-3,
the GluN1-3 C-terminus was appended, from lysine 859 (GluN1-1B
sequence) to an EGFP-tagged mutant of vesicular stomatitis viral
glycoprotein (VSVGts045; Fig. 1A). VSVGts045–EGFP (VE) is a well-
characterized viral glycoprotein mutant that remains unfolded,
ER-localized, and chaperone-bound at 40 °C, and rapidly folds correctly
and exits the ER when the temperature is switched to 32 °C [19]. By
appending the GluN1 C-terminus (Fig. 1B) at the C-terminus of EGFP,
the rate of ER exit could be assessed in multiple ways (Fig. 1C). Prelimi-
nary experiments veriﬁed that the ER retention signal in GluN1 was
both operational and dominant to the previously characterized ER exit
motifs [25,34] on the VE C-terminus (Fig. S1).
After the effect of SAP97 on ER exit was established, segments and
chimeras of the L27, PDZ, SH3, and GuK domains of SAP97 were tested
with the GluN1-3 C-terminus appended to IL2RA (Tac; Fig. 1D), a type
I transmembrane protein,which has been extensively used as a reporter
molecule for trafﬁcking studies [23,31,37]. This was performed to
identify which structural elements of SAP97 mediate the blockade of
ER retention.
2.1. Effects of SAP97 on trafﬁcking of GluN1-3
COS-1 cells were transfected with VE–GluN1-3 (VE1-3) and
SAP97 (Fig. 2A, top), or VE1-3 and pcDNA3.1 (empty vector) over-
night (Fig. 2A, bottom), placed at 40 °C for 24 h, then ﬁxed, and
immunolabeled with antibodies against the ER marker, calnexin,
and SAP97 (Fig. 2A). VE1-3 was nearly identically co-localized with
calnexin in the presence and absence of SAP97 when maintained at40 °C (presence, Rcoloc = 0.79 ± 0.02; absence, Rcoloc = 0.81 ±
0.03; N = 72 cells; Rcoloc is Pearson's coefﬁcient above the Costes
threshold). To further ensure that SAP97 did not affect VE1-3 subcellu-
lar distribution at non-permissive temperature, cells were transfected
as described above and lysates subjected to control, endoglycosidase
H (Endo H), and N glycosidase F (NGF) treatments, and then proteins
were separated by SDS PAGE and immunoblotted with anti-VSVG
antibody (Fig. 2B). The results indicated that all constructs of VE1-3
remained sensitive to Endo H treatment in the presence of co-
transfected SAP97.
To assess the inﬂuence of SAP97 on VE1-3 trafﬁcking along the
secretory pathway, cells transfected with VE1-3 and pcDNA3.1, or
VE1-3 and SAP97 were maintained at 40 °C for 24 h, and then switched
to 32 °C for 1 h. After 1 h at 32 °C, VE1-3 plus pcDNA3.1 was still
localized almost completely with calnexin (Fig. 2C, top panels). Co-
transfection with SAP97 resulted in EGFP ﬂuorescence consistent with
the localization to the Golgi and endosomes (Fig. 2C, bottom row,
white arrows). Loss in co-localization (ΔRcoloc) of VE1-3 ﬂuorescence
with calnexin immunoﬂuorescence was quantiﬁed following 1 h incu-
bation at 32 °C with and without SAP97 (Fig. 2D). After 1 h, the differ-
ence in loss of co-localization with calnexin was about 2 1/2 fold
greater than without SAP97 (VE1-3 ΔRcoloc = −0.12 ± 0.03 and
+SAP97 ΔRcoloc = −0.30 ± .05; *p b 0.01; n = 134 cells total).
These data suggested that SAP97 increased the exit of VE1-3 from
the ER. However, since PDZ proteins have been characterized as having
many effects on trafﬁcking, the result was conﬁrmed in several
other ways.
To determine if SAP97 was affecting the rate of trafﬁcking of VE1-3
through the secretory pathway, an ELISA similar to that described previ-
ously [37] was performed. Cells were incubated for 24 h at 40 °C and
switched to 32 °C for various periods of time (from 45 min to 6 h),
and the incubation was terminated for analysis. Cell surface and total
VE expression was assessed using the I1 antibody. The addition of the
GluN1-3 C-terminus had a profound effect on the surface and total
levels of expression (Fig. 2E; compare closed circles to closed
diamonds). Co-transfection of SAP97 with VE1-3 resulted in a greater
than 2-fold increase in cell surface versus total expression ratio
(Fig. 2E; compare closed squares to closed circles).
The changes in surface levels as a function of time from Fig. 2E were
ﬁtted to a simple association kinetic function, y = Ymax(1 − e−kt),
which indicated that the rate of surface expression (k) was not signiﬁ-
cantly different across the various groups (VE, VE1-3, or VE1-3 +
SAP97; 1.9 ± 0.18, 1.66 ± 0.34, and 2.02 ± 0.36, respectively). On the
other hand, the maximum surface expression (Ymax) was signiﬁcantly
different in all three groups (VE = 0.68 ± 0.03†; VE1-3 = 0.18 ±
0.01; VE1-3 + SAP97 = 0.44 ± 0.02†; †p b 0.05, ANOVA with post hoc
comparisons). These data indicated that SAP97 did not signiﬁcantly
affect the rate of trafﬁcking along the secretory pathway. Instead,
SAP97 altered the amount of VE1-3 introduced immediately into the
secretory pathway. These ﬁndings also indicated that the expression
of other signals, such as exit signals, present on both VE [25] and the
GluN1-3 C-terminus [23], which have been shown to affect the rate of
forward trafﬁcking, was not altered signiﬁcantly across groups.
VE has two asparagine-linked glycosylation sites that become resis-
tant to Endo H at the medial-Golgi apparatus [32]. This transition in
sensitivity was used to corroborate the differences observed in the
loss of calnexin co-localization. Cells maintained at 40 °Cwere switched
to 32 °C for 3 h and placed on dry ice, and cell lysates were prepared for
deglycosylation treatment and SDS PAGE. Immunoblots with anti-C2′
antibody and anti-SAP97 of treated and control samples demonstrated
a difference in preservation of the upper Endo H resistant band of
VE1-3 in the presence of SAP97 (Fig. 2F). Note that the upper band
(black arrow in Fig. 2F, right) in the Endo H-treated lane is more prom-
inent with SAP97 than without it. Quantitative analysis (Image Studio)
indicated that the ratio of upper to lower bands was 1.5-fold greater
in the presence of SAP97. This assaywas performed 3 timeswith similar
Fig. 1. Experimental strategy and background. (A) To assess the effect of PDZ proteins on GluN1-3 exit from the ER, the C-terminus was appended to VE (VE1-3). (B) The last two exons
coding for the C-terminus GluN1 are alternatively spliced, and have either the C1 splice cassette, or not, joined to theC2 or C2′ splice cassette. The possible sequence determinants affecting
ER retention and ER exit are shown for the different GluN1 C-termini. The PDZ-binding domains are underlined. The ER retention motif is indicated by three asterisks (***). PKC and PKA
phosphorylation sites are shown as double-daggers (‡‡). GluN1-3 and GluN1-4 have a nested di-valine exit signal in the PDZ-binding motif, which has been shown to speed forward
trafﬁcking (++). (C) When cells are maintained at 40 °C, VE remains unfolded and chaperone-bound in the ER, but mobile [19], and when they are shifted to 32 °C, VE rapidly folds
correctly and exits the ER in awave, which can be assessed by: 1) changes in co-localizationwith subcellularmarkers, 2) Endo H sensitivity of two N-linked glycans on VE, and 3) antibody
labeling to cell surface VE. Since the rate of ER exit and traversal of the secretory pathway can be accurately assessed, appending the GluN1-3 C-terminus to VE and co-transfecting with
prospective interacting proteins were used to identify interacting proteins that could enhance ER-exit. (D) IL-2α has been used extensively as a trafﬁcking reporter for analysis of
trafﬁcking determinants. An excellent monoclonal antibody hybridoma is available (7G7B6; ATCC) for immunoﬂuorescence, ELISAs, and immunoprecipitation. For analysis of secretory
trafﬁcking by Western blot, IL2RA is extensively glycosylated such that the cell-surface form is about 25 kD larger than the immature form localized early in the secretory pathway.
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however, it can be explained. The GluN1-3 C-terminus has an RXR ER
retentionmotif that binds COPI [22], and a di-valine (-VV) ER exit signal
on the extreme C-terminus that binds COPII [23], similar to ERGIC-53,
which has a di-lysine motif (KKXX) that also binds COPI, and a di-
phenylalanine ER exit signal (-KKFF) that binds COPII. Because of
these motifs, ERGIC-53 moves from the Golgi to ER, and back again, in
cycles [10]. ERGIC-53 is also glycosylated and is Endo H resistant [26].
Thus, it is quite likely that, with the same set of trafﬁcking motifs,
some of theVE1-3 cycles between theGolgi and ER in the 3 h permissive
time period. This could allow the processing of some VE1-3 in the Golgi
to Endo H resistant form, with a subsequent return to the ER.
The effect of SAP97 on the GluN1-3 C-terminus was assessed in two
additional ways: by loading ER-localized VE1-3 into the intermediate
compartment (IC) at 15 °C for 1 h in the presence and absence of
SAP97 (Fig. S2), and by assessing the effect of siRNA knockdown of
endogenous SAP97 on Tac1-3 surface expression (Fig. S3). Brieﬂy, the
effect of SAP97 on the amount of VE1-3 traversing from the ER to the
IC and co-localizing with a marker of the late IC was quantiﬁed. SAP97
induced greater co-localization of VE1-3 with late IC, indicating thatSAP97 affects the ER exit of VE1-3. Secondly, SAP97 siRNA knockdown
of endogenous SAP97 in Hela cells showed a profound reduction in
the relative cell surface expression of Tac1-3 compared to scrambled
control siRNA. This suggested that the small amount of endogenous
SAP97 in Hela cells has a central function in the ER exit of the GluN1-3
C-terminus.
2.2. Role of the SH3–GuK domains of SAP97
To determine how SAP97 blocked the ER retention of theGluN1-3 C-
terminus, SAP97 truncationmutants and fragmentswere co-transfected
with VE1-3. ELISAs were performed after 3 h at 32 °C (Fig. 3A). Prior
work suggested that PDZ domain binding was directly involved in
blocking ER retention [13]. To ﬁrst determine whether PDZ domain
binding to the GluN1-3 C-terminus was sufﬁcient to suppress ER reten-
tion, PDZ1-3 domains tagged on the C-terminus with GFP were co-
transfected with VE1-3 and the effects assessed (Fig. 3A; see +PDZ1-3
only). The PDZ-domains of SAP97 did not increase forward trafﬁcking
3 h after 32 °C. The PDZ domains of SAP97 alone tended to inhibit
forward trafﬁcking, although not signiﬁcantly (p b 0.10; Fig. 3A). This
Fig. 2. SAP97modulates ER exit of theGluN1-3 C-terminus. (A)When cellsweremaintained at 40 °C, VE1-3 co-localizedwith calnexin in thepresence (top row) and absence (bottom row;
scale bars: 10 μm) of SAP97. Merges show co-localization of VE1-3 with calnexin in each case. (B) SAP97 did not inﬂuence VE1-3 ER exit when cells were maintained at 40 °C. Cells were
transfectedwith VE1-3 and SAP97 andmaintained at 40 °C for 24 h; cell lysates were subsequently treatedwith Endo H (center), and N-glycosidase-F (N-G-F). Immunoblots indicated no
detectable resistance to Endo H. (C) 1 h after switching to 32 °C, VE1-3 remained co-localized with calnexin (top row). Co-transfection of SAP97 resulted in the increased appearance of
perinuclear and vesicular ﬂuorescence (white arrows, bottom row, left) and endosomes (scale bar: 10 μm). (D) Co-localizationwith the ERmarker calnexinwas assessed at time 0 and 1 h
after switching to 32 °C. Co-localization of VE1-3 with ER markers at time 0 was 0.85 ± 0.03 (Rcoloc, ±SEM) and decreased after 1 h by−0.12 ± 0.02 whereas SAP97 co-transfection
signiﬁcantly decreased ER localization after 1 h compared to VE1-3 alone (−0.30 ± 0.05; p b 0.01). (E) SAP97 increased surface delivery of VE1-3. Surface and total (permeabilized
labeling) ELISAs were performed at various time points after switching to 32 °C for transfected VE (closed diamonds), VE1-3 alone (closed circles), or VE1-3 co-transfected with SAP97
(closed squares). VE, VE1-3, and VE1-3 + SAP97 were added to the cell-surface in signiﬁcantly different amounts, with SAP97 causing a 2–3 fold increase in cell-surface VE1-3, as
compared to VE1-3 alone. (F) SAP97 increases Endo H resistance 3 h after at 32 °C. VE1-3 was transfected in the presence or absence of SAP97, and cells shifted to 32 °C for 3 h after
24 h at 40 °C, and cell extracts subjected to control, Endo H treatment. Immunoblots using anti-C2′ antibody (top panels) and anti-SAP97 (bottom) of the same samples show increased
Endo H resistance with SAP97. This was repeated 3 times with similar results. The black arrow indicates Endo H resistant molecular weight.
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treme C-terminal di-valine motif of GluN1-3 [23]. This result suggested
that prolonged association of SAP97 PDZ domains with the extreme
C-terminus may interfere with the exit signal function of the di-valine
motif of GluN1-3 at ER exit sites by competing with COPII. Also, it
appears unreasonable to expect masking of the ER retention domain
by SAP97 PDZ domains since the amino acid sequence required for
speciﬁc binding of PDZ domains to their respective ligands is as little
as 3 amino acids [35]. Alternatively, truncation of the GuK domain,
and then truncation of the SH3–GuK domains together had a succes-
sively diminishing effect on forward trafﬁcking of VE1-3, as comparedto full-length SAP97, with truncation of the SH3–GuK causing a signiﬁ-
cant decrease (Fig. 3A; **p b 0.05, ANOVA with post hoc comparisons).
The expression levels of SAP97 and SAP97ΔSH3–GuK were then
assessed in comparison to β-actin (Fig. 3B) and were not signiﬁcantly
different (N = 3 per group; SAP97 = 4.03 ± 0.57; SAP97ΔSH3–
GuK = 4.8 ± 0.93; Student's t-test, 0.5). Since ER retention signals are
usually blocked by protein–protein interactions and steric masking,
we ﬁrst tested whether or not the GuK domain of SAP97 alone could
bind the GluN1-3 C-terminus, N-terminal to the PDZ-binding domain.
Co-transfection of Tac1-3Δ4 with the GFP–GuK of SAP97 demonstrated
striking co-localization compared to Tac1-3Δ4 co-transfected with GFP
Fig. 3. An SH3–GuK domain interaction is necessary for GluN1-3 ER exit. (A) Surface versus total ELISAswere performed at 3 h after switching cells to 32 °Cwith co-transfected VE1-3 and
SAP97, or VE1-3 and cotransfected truncated segments of SAP97. Co-transfections of PDZ1-3 domains resulted in diminished surface expression. Successive removal of the GuK domain,
and SH3–GuK domains of SAP97 resulted in a signiﬁcant loss of cell-surface VE1-3 (**p b 0.05, ANOVA, post hoc comparisons), indicating that the SH3–GuK domains may be necessary to
suppress ER retention of GluN1-3. (B) Expression levels of SAP97 and SAP97ΔSH3–GuK were assessed by immunoblotting transfections with anti-SAP97 antibody and anti-β-actin to
control for load. No difference was observed. (C) Tac1-3Δ4 co-localized with GuK and SH3. Immunoﬂuorescence micrographs of Tac1-3Δ4 co-expressed with EGFP control showed no
shared edges and minimal co-localization (top row; scale bars: 10 μm). Tac1-3Δ4 co-expressed with EGFP–GuK showed striking co-localization (middle row). Tac1-3Δ4 showed co-
localization with the SH3–GFP domain as well (bottom row; yellow arrows indicate shared edges). (D) Co-immunoprecipitation experiments (repeated 4 times with similar results)
indicated that the SH3 and GuK domains interacted with the GluN1-3 C-terminus. Cells co-transfected with Tac1-3Δ4 and EGFP, EGFP–GuK, or SH3–EGFP were lysed, prepared, and
subjected to immunoprecipitation with 7G7B6 antibody and SDS PAGE. Blots on the left were probed with anti-human IL2RA antibody to conﬁrm immunoprecipitation. Blots on the
right were probed with anti-GFP antibody. Panels show input (5%; In), I.P. (25%), and unbound (Un).
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Tac1-3Δ4 also exhibited some co-localization (Fig. 3B, bottom panels;
yellowarrows). Physical interactionswere conﬁrmedby immunoprecip-
itationwith 7G7B6 antibody and probing for co-immunoprecipitation of
GFP–GuK and SH3–GFP with Tac1-3Δ4, and not with GFP, using rabbit
anti-GFP antibodies (Fig. 3C).
2.3. ER retention of GluN1-3 is blocked by the SH3 domain of SAP97
Since the SH3–GuK domains were necessary to suppress ER
retention, the Tac reporter was appended with the GluN1-3 C-terminusand the last 4 amino acid PDZ-binding domain was deleted to fur-
ther determine if these modular domains were sufﬁcient to sup-
press ER retention (Fig. 4). Tac1-3Δ4 was co-transfected with
GFP, GFP–GuK, or SH3–GFP, and surface immunolabeling with Tac
antibody to Tac1-3Δ4 was performed (Fig. 4A, top panels; compare
GFP ﬂuorescence in left panels with surface labeling in right
panels). Images were captured using identical settings, and bright-
ness and contrast were manipulated similarly for comparison. GFP
had no effect on surface expression (Fig. 4A, top right panel), GFP–
GuK had a small positive effect (Fig. 4A, center row), and SH3–GFP
causedmuchmore intense surface labeling (Fig. 4A, bottom panels;
Fig. 4. The SAP97 SH3 domain is sufﬁcient to block ER retention. (A) Cell surface immunoﬂuorescence immunolabeling of cells transfected with Tac1-3Δ4 and GFP (top row), or GFP–GuK
(middle row), or SH3–GFP (bottom row)wasperformed as described inMaterials andmethods. Imageswere taken at lowmagniﬁcation (10×; scale bar: 100 μm)with the same settings for
comparison. Left column shows GFP ﬂuorescence, and the right column shows surface labeling of Tac1-3Δ4. Tac1-3Δ4 + GFP surface labeling showed background immunoﬂuorescence
(upper right picture), +GFP–GuK showed modest surface labeling coincident with GFP ﬂuorescence (middle right; see arrows), and Tac1-3Δ4 showed saturating ﬂuorescence on some
cells that co-expressed SH3–GFP (bottom right; top two white arrows). This experiment was repeated more than 3 times with similar results. (B) Western blots of Tac1-3Δ4 alone or
co-transfectedwith SH3–GFP, or GFP–GuK, full length SAP97, or full-length Tac1-3 probedwith anti-IL2RA antibody (lanes indicated aboveblot) demonstrated that Tac1-3Δ4 alone showed
only the immature, ER-localized band, whereas SH3–GFP co-expression caused a shift to mature Tac1-3Δ4 that was similar to the full length C-terminus, Tac1-3. Tac1-3Δ4 co-expression
with full-length SAP97 showed only a small amount of mature form. (C) Surface versus total ELISAs with Tac1-3, andmutants, co-transfected with segments or chimeras of SAP97. Tac1-3
surface expressionwas signiﬁcantly greater than Tac1-3Δ4 (††p b 0.01, one-way ANOVA, post hoc comparisons; N=number of independent transfections). Co-expression of Tac1-3Δ4with
the GFP–GuK domain and SH3–GuK–GFP domains resulted in no signiﬁcant change in surface expression. Fusion of the N-terminal 120 amino acids with the SH3–GuK domain of SAP97
(Wu–GFP) co-expressedwith Tac1-3Δ4 resulted in signiﬁcant suppression of ER retention (†p b 0.05, ANOVA, post hoc comparisons). The SH3–GFP domain of SAP97 alonewas sufﬁcient to
block ER retention of Tac1-3Δ4 (††p b 0.01, ANOVA, post hoc comparisons), conﬁrming the results in (A) and (B). Co-expression of full-length SAP97with Tac1-3Δ4 resulted in only a small
and insigniﬁcant increase in surface expression. (D) Deletions, segments, and fusions of βSAP97 used in this study.
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on surface expression were further conﬁrmed by Western blot of
Tac1-3Δ4 transfected alone, with SH3–GFP, GFP–GuK, full-length
SAP97, or Tac1-3 for comparison (Fig. 4B). The immature form of
Tac1-3Δ4 is the band migrating at approximately 50 kD (Fig. 4B,
white arrow), which represents the ER-localized form. The band
that appears at about 70–75 kD represents the fully-glycosylated
form that has passed through the Golgi apparatus (Fig. 4B, black
arrow). Transfected alone, Tac1-3Δ4 remained in an immature,
ER-localized form, whereas co-transfection with SH3–GFP profoundlyincreased the mature, cell-surface form (Fig. 4B; compare left two
lanes at black arrow). In fact, SH3–GFP reproduced the relative
distribution obtained with the PDZ-binding domain intact (Fig. 4B,
second lane from the right). Although GFP–GuK associated with
Tac1-3Δ4, it had little to no effect on its surface trafﬁcking. Full-
length SAP97 also had little effect on Tac1-3Δ4 ER exit, indicating
that suppression of ER retention by the full-length SAP97 requires a
PDZ-domain interaction to initiate SH3–GuK binding to the GluN1-
3 C-terminus. This result was corroborated in ELISA assays shown
in Fig. 4C.
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The surface expression of Tac1-3 and mutants was tested with
SAP97, or mutants, in an ELISA using Tac antibodies (Fig. 4C).
Tac1-3Δ4 surface expression shown in Fig. 4C was at the background
level only, as was previously observed. The various truncations, seg-
ments, and chimeric constructs used are described in Fig. 4D. Co-
transfection of the GuK domain with GFP attached (Fig. 4C, Δ4 +
GFP–GuK) had little effect. On the other hand, the SH3–GFP construct
produced surface expression levels nearly equal to the full-length
Tac1-3 (Fig. 4C, compare Tac1-3 with Δ4 + SH3–GFP).
Previous work has demonstrated that the SH3–GuK domains fold
over onto one another to form a ‘sandwich’, limiting their exposure to
potential interacting proteins, and that the N-terminus of SAP97modu-
lates the availability of SH3–GuK to other binding partners [39]. This
was shown by appending the N-terminal 120 amino acids of SAP97
directly to the SH3–GuK domains, which facilitated the binding of
GKAP to the GuK domain. Wu et al. [39] demonstrated that without
the N-terminus, the GuK domain could not be made available to
GKAP. Given that both the SH3 and GuK domains bind the GluN1-3
C-terminus, and that the SH3–GuK segment does not appear to block
ER retention (Fig. 4C, Δ4 + SH3–GuK–GFP), it was reasoned that the
N-terminus of SAP97 may be additionally required to open the SH3–
GuK sandwich and functionally suppress the ER retention of Tac1-3Δ4.
In support of this, co-transfection of the N-terminus/SH3–GuK (GFP)
chimera with Tac1-3Δ4 signiﬁcantly increased surface expression
(Fig. 4C, Δ4 + Wu–GFP), whereas the SH3–GuK (GFP) domains alone
did not.2.5. SAP97 increased the surface expression of GFP–GluN2B/GluN1-3B
Veriﬁcation of the effects of SAP97 was sought on full-length NMDA
receptors. Because there were low levels of SAP97 immunolabeling and
no observable surface expression of NMDA receptors in newly obtained
Hela cells (ATCC), they were used to assess the effects of SAP97 on full-
length GFP–GluN2B/GluN1-3B. Hela cells were transfected with equal
amounts of DNA (for each group, 3 separate transfections) encoding
GFP–GluN2B, GluN1-3B, with pcDNA3.1 control, or an equal amount
of SAP97. Hela cells were immunolabeled on the cell surface with a
mouse anti-GFP antibody at room temperature (RT) for 45 min 24 h
after transfection in the presence of 50 μM AP5, then ﬁxed, perme-
abilized, and immunolabeled with rabbit anti-SAP97 antibodies
(Fig. 5A). GFP–GluN2B was surface immunolabeled because it is well-
established that GluN2B transfected alone in heterologous cells and
even in neurons from GluN1 mouse knockout remains ER-localized [5].
Surface expression in the pcDNA3.1 control group showed near-
background levels of surface labeling, as compared to robust surface
labeling observed with co-transfected SAP97 (Fig. 5A, compare top left
to bottom left). The GFP–GluN2B surface labeling appeared to correlate
well with the intensity of SAP97 immunolabeling (Fig. 5A, compare
numbered cells in SAP97 ﬁeld to GFP–GluN2B surface ﬁeld). The effect
of SAP97 co-transfection on GFP–GluN2B/GluN1-3B surface expression
was highly signiﬁcant (Fig. 5B; p b 0.01, Student's t-test) and surface
labeling was well-correlated with SAP97 intensity (Fig. 5B, right
panel), but not GFP–GluN2B intensity (data not shown). This indicated
that full-length SAP97 was responsible for profoundly increasing the
surface expression of full-length GluN2B/GluN1-3 receptors, and
corroborated the results obtained with VE- and Tac-reporters. Also, the
SAP97 SH3 domain was sufﬁcient to increase the surface expression of
full-length mycGluN2B/GluN1-3B receptors (Fig. S4A–B). Note that
SAP97 did not appear to cluster NMDA receptors (for example,
Fig. 5C), as has been previously reported. SAP97 has been reported to
cluster some binding partners [38] and to bind GluN2B–GluN1-1
heteromers [3] through the PDZ-binding domain of GluN2B. It appears
that in this case, SAP97 suppresses the ER retention of GFP–GluN2B/GluN1-3, but the fate of SAP97 after blocking ER retention with respect
to the PDZ binding domains of GFP–GluN2B and GluN1-3B is unclear.
3. Discussion
Few studies have analyzed functional interactions between recep-
tors or ion channels and modular MAGUK domains other than the PDZ
domains. This work uniquely identiﬁes the receptor–PDZ interaction
as an initial trigger for other non-PDZ domain interactions. In every
case so far, truncating the extreme C-terminus PDZ-binding domain
abrogates binding between the receptor/ion channel C-terminus and
PDZ domain containing proteins. Given the different allosteric states of
MAGUKs in particular [18,24], and knownmechanisms that limit access
to MAGUK modular domains [21,39], the concept of PDZ binding
triggering downstream, non-PDZ domain interactions may well be a
general one. This manuscript raises the possibility that much may
have been overlooked regarding receptor/PDZ protein interactions.
The use of chimeric reporter constructs of the NMDA receptor
C-terminus has already contributed substantially to our understanding
of NMDA receptor trafﬁcking [33,37,40]. By using chimeras of VE and
the NMDA receptor C-terminus, SAP97, a protein known to interact
with the GluN1-3 PDZ-binding domain, was identiﬁed as a PDZ protein
that blocks ER retention. The approach taken allowed better character-
ization of the effect of SAP97 on ER exit, and provided a detailed descrip-
tion of the rules of an unexpected mechanism of action. PDZ binding
appears to be necessary, but not sufﬁcient for blocking ER retention.
Moreover, persistent association of SAP97 PDZ1-3 with GluN1-3
appears paradoxically to inhibit forward trafﬁcking. It is proposed that
PDZ binding represents the initial interaction between SAP97 and
GluN1-3, and functions as a trigger to initiate the downstream blockade
of the GluN1-3 ER retention signal through SH3–GuK binding to the
C-terminus. Secondly, it is proposed that SAP97 PDZ binding to
GluN1-3 may be a short-lived interaction, and is perhaps displaced by
the SH3–GuK domains themselves. At the molecular level, these results
impose requirements that seem, at face value, to be difﬁcult to reconcile
spatially. A simple model is proposed, which is not meant to explain
every detail, but satisﬁes the requirements imposed to the extent
discernible (Fig. 6). The requirements for blocking ER retention have
been made clear in this study; however further experimentation will
be necessary to work out the precise molecular dynamics of this
SAP97 function.
3.1. Modulating the availability of SH3 and GuK domains
A similar set of interactions between the N-terminus of SAP97
and the SH3 and GuK domains has been shown previously to regu-
late the association of GKAP with the GuK domain of SAP97 [39].
The present ﬁndings support the requirement for an additional PDZ
binding domain interaction with the NMDA receptors. The SH3 and
GuK domains have been shown to fold onto each other to form a
sandwich that appears to limit the availability of SAP97 SH3–GuK
domains to potential binding partners. Herein, it is shown that a sim-
ilar set of interactions controls an exquisite trafﬁcking function by
sterically blocking the ER retention signal in GluN1-3. The SH3 and
GuK domains of SAP97 have also been shown to interact with
the kainate receptor subunit, GluK5, but it was found that the N-
terminus of SAP97 played a role in inhibiting the opening of SH3–
GuK to bind the C-terminus of GluK5 [21]. It should be noted that
those conclusions were drawn from studies with the GluK5 receptor
subunit only, and in the absence of GluK2, its cognate subunit. KA2
does not have a PDZ-binding domain. Since SAP97 binds to GluK2
through a PDZ-binding domain interaction [21], it is quite possible
that the same dynamic interaction observed in this study between
GluN1-3 and SAP97 is elicited by an initial interaction between
SAP97 and the PDZ-binding domain of GluK2 in trans. These ﬁndings
may represent the beginning of a more general set of mechanisms
Fig. 5. Cell surface expression of GFP–GluN2B/GluN1-3 is dramatically increased with SAP97. GFP–GluN2Bwas transfected in Hela cells with GluN1-3B and an equal amount of pcDNA3.1
or SAP97 vector. (A) Surface labeling in the presence of SAP97 (top panels; scale bar: 100 μm) or pcDNA3.1 (bottom panels). Note that an increase in SAP97 resulted in increased surface
immunolabeling intensity; compare cells labeled 1–3 in each upper panel. (B) Three separate transfections for each groupwere performed to quantify surface labeling of anti-GFP antibody
24 h after transfection in the presence of 50 μMAP5. Average intensity of surface immunolabelingwas quantiﬁed (60 cells total for pcDNA3.1 and 91 cells for ‘plus SAP97’; **p b 0.01). The
intensity of SAP97 ﬂuorescence was well correlated with the intensity of surface labeling (B, right panel). (C) Higher magniﬁcation (60×, 2× zoom; scale bar: 10 μm) shows the typical
surface and subcellular distribution of cells co-transfected with GFP–GluN2B, GluN1-3B, and SAP97. Note that SAP97 does not cluster GluN2B/GluN1-3 and does not show strong co-
localization with GFP ﬂuorescence.
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main of SAP97 additionally binds ADAM10, but the full-length
SAP97 does not appear to suppress an RXR motif on its cytoplasmic
C-terminus [20]. In light of these ﬁndings, it is possible that SAP97-
mediated blockade of the RXR motif of ADAM10 depends on co-
translation and co-transport of a PDZ binding domain-containing
protein to trigger SAP97-mediated block of ER retention. An even
more exciting possibility is that the ER retention signal is blocked
by a different SH3 domain, which would suggest a more general
mechanism. In any case, this is the ﬁrst evidence of SH3 domain-
mediated blocking of ER retention signals, but it is likely not the last,
as the requirements for atypical SH3 binding dovetail with the
requirements for ER retention signals. Finally, with respect to SH3
domains potentially blocking other ER retention signals, RXR ER re-
tention signals have been described for ADAM10 and KA2, and both
have consensus (PXXPX+; +XPXXP) SH3 binding motifs (http://
cbm.bio.uniroma2.it/SH3-Hunter/) proximal to those ER retention
signals [12,20]. It will be of great interest to determine how broadly
this mechanism applies.3.2. SAP97 works both ways
Beta-forms of SAP97 have been shown to retain their interacting re-
ceptors or ion channels in the ER [15,38]. In this study, itwas shown that
SAP97 exports a splice variant, GluN1-3, of an ER retained receptor,
GluN1-1, by default. GluN1-3/4 receptor subunits are expressed early
in development and under conditions of inactivity induced by AP5. It
is proposed that SAP97 performs a binary function at the ER level,
ejecting cargo by default into a conventional secretory pathway and
regulating entry into the non-conventional one. In support of this, re-
cent evidence indicated that the conformation of SAP97 might explain
the entry of GluR1 into the global conventional pathway or of GluN1-
1/GluN2A/B into the local, non-conventional pathway [18]. βSAP97
has also been shown to inhibit forward trafﬁcking of Kv1.4 out of the
ER [38] and βSAP97 inhibits forward trafﬁcking of GluN2–GluN1-1a
splice variant-containing NMDA receptors out of the ER [15]. This func-
tion affords the potential to modulate ER exit with additional signals or
protein interactions. By co-expressing CASK, which binds to the L27 do-
main in the N-terminus of βSAP97, the ER retention of GluN2/GluN1-1
Fig. 6. Provisionalmodel of SAP97-mediated block of GluN1-3 ER retention. (A) GluN1-3 subunits are blue, andNR2s are orange. The ER retention signals of GluN1-3 subunits are depicted
by black ovals. βSAP97 forms compact monomers, extended monomers, and dimers [24], and the model predicts the initial interaction results in binding of a compact monomer in the
absence of CASK that may cycle between compact and extended states (B). (C) The L27 domain ( ) of a second molecule could then interact with the SH3–GuK sandwich [39] of
the other, and vice versa. In the anti-parallel conﬁguration, the L27 domains interact with, andmodulate opening of the SH3–GuK sandwich of the opposing SAP97molecule. PDZ domain
binding ( ) occurs ﬁrst (black two-way arrows), since removal of the PDZ-binding domain blocks the entire interaction and effect. PDZ binding to the GluN1-3 C-terminus situates the
GuK ( ) domain of the opposingmonomer to bind and displace the PDZ domain. (D) In an open conﬁguration, the SH3 domain ( ) binds to the SH3 bindingmotif embedded in the RXR
ER retention motif. The resulting SH3–GuK binding leaves the extreme C-terminal di-valine motifs of GluN1-3 (red endings), which becomes available to bind COPII.
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of SAP97 could be triggering an ER-exit event similar to that of the PDZ
domain interaction that triggers blockade of the ER retention of GluN1-
3 shown here. The GluN1-3 action does not require co-expression of
CASK, and occurs by default interaction with βSAP97 at the ER level.
The facilitation of ER exit is further expedited by the C-terminal
di-valine binding to COPII, which is linked primarily to conventional
secretion through the Golgi apparatus [8]. It is not knownwhether the in-
stant non-conventional secretory pathway of NMDA receptors in neurons
is mechanistically similar to the non-conventional secretory pathways
that bypass the Golgi apparatus and do not require COPII binding. In
particular, the non-conventional NMDA receptor pathway appears to
involve at least early elements of the Golgi apparatus [15]. There is evi-
dence that other Golgi elements are present in dendrites and proximal
to postsynaptic sites in neurons [6], but the precise nature of the non-
conventional secretory pathway of someNMDA receptors—the organellar
and molecular elements and signals that fully distinguish this pathway
from the conventional secretory pathway—remains to be determined.
4. Materials and methods
4.1. Antibodies
I1 hybridoma was a generous gift from Doug Lyles (Wake Forest),
and has been characterized previously [16]. Rabbit anti-VSVGantibody was a generous gift from Carolyn Machamer (Johns
Hopkins), and has been characterized previously [34]. Anti-SAP97
monoclonal antibody was from Stressgen (Victoria, B.C.), and
mouse anti-SAP97 was from Enzo Life Sciences (RPI 197.4). Rabbit
anti-SAP97 was from Thermo Scientiﬁc (PA1-044). Rabbit polyclonal
anti-C2′ antibody was from Pierce. Goat anti-human IL2RA antibod-
ies used for Western blots were from R&D Systems. The 7G7B6
hybridoma was acquired from ATCC. Monoclonal anti-GFP (Thermo
Scientiﬁc; GF28R) for surface labeling using GFP–GluN2B has been
characterized previously [11]. Rabbit anti-GFP antibody was from
Sigma. Rabbit anti-calnexin antibody was from Abcam. 9E10 anti-
myc hybridoma was obtained from DSHB (Iowa). Anti-GM130 anti-
body was obtained from BD Transduction Laboratories. Cross-
adsorbed Alexa-350, Alexa-405, Alexa-488, Alexa-555, Alexa-594,
and 633-conjugated mouse and rabbit anti-IgG antibodies from Life
Technologies were used for both representative micrographs and
quantitative measurements. GluN1 anti-C2 domain rabbit antibodies
were a gift from Ronald Petralia (NIDCD).4.2. Deglycosylation
Deglycosylation was performed as previously described [37].
Endo H and N-glycosidase F were obtained from New England
Biosciences.
498 X. Hong et al. / Biochimica et Biophysica Acta 1853 (2015) 489–4994.3. Immunoprecipitation and Western blotting
Immunoprecipitations were performed using the Pierce Classic
IP kit and following the instructions. 7G7B6 hybridoma superna-
tant was used for immunoprecipitations and anti-GFP and goat
anti-IL2RA for Western blots. SDS polyacrylamide gel electropho-
resis was performed with gels ranging from 8% (Fig. 2, 4, and S1)
to 10% (Fig. 3) and transferred to Immobilon P®. Immunoblots
were blocked with Odyssey blocking buffer overnight, incubated
with antibodies for at least 1 h at RT or overnight at 4 °C in block,
then incubated with Odyssey 680 or 800 ﬂuor-conjugated second-
ary antibodies. Blots were then imaged on an Odyssey imaging
system.
4.4. siRNA knockdown
Knockdown of endogenous SAP97 in Hela cells was performed using
DLG1 (SAP97) trilencer siRNA (Origene, Rockville, MD) and scrambled
control according to the manufacturer's protocol.
4.5. DNA constructs
cDNA constructs were generously provided by the following:
PSD-95, David Bredt (Johnson & Johnson); SAP97 (I2I5I4 U5
domain splice variant), Craig Garner (Stanford); GluN1-1B and
GluN1-3B, Michael Hollmann (Ruhr University Bochum); GFP–
GluN2B, Stefano Vicini (Georgetown University); and mycGluN2B,
F. Anne Stephenson (University College, London). VE was subcloned
into the pcDL vector via XhoI/EcoRV sites. An XbaI site was added
in-frame, beginning at the stop codon for EGFP, by site-directed
mutagenesis using a Quickchange kit from Agilent Technologies. Be-
cause the GluN1-3 tail DNA sequence contains an EcoRV site, GluN1-
3 (amino acids 859 to 944) was subcloned into only the XbaI site of
VE, and then sequenced. The EGFP of VE was substituted with
dsRED2 (VR) by generating a PCR product with oligonucleotides
to EGFP–dsRed2 and the VE C-terminus, then using Quickchange
Site-directed mutagenesis kit as described [7]. The C-terminus of
GluN1-1 was subcloned into VR via a 5′ XbaI site added in-frame
VR and a 3′ EcoRV site.
The IL-2α reporter with an XbaI site in-frame on the C-terminus at
amino acid 269, and a 3′ EcoRV site in the pcDL polylinker in pcDL
was obtained from the laboratory of Robert Wenthold (NIDCD, Bethes-
da, MD). The GluN1-3 C-terminus (amino acids 858–943 of GluN1-3B)
was subcloned into the Tac reading frame at the XbaI site. Site-
directed mutagenesis was performed to obtain Tac1-3Δ4, and Tac1-
3K898A, Δ4. Mutants were sequenced for accuracy and orientation
(GeneWhiz, La Jolla, CA).
βSAP97 truncation mutants ΔGuK and ΔSH3–GuK (amino acids
1–710 and 1–570 of SAP97, respectively) and GluN1-3BΔ4 were cre-
ated using the Quickchange site-directed mutagenesis kit. To recre-
ate the construct of [39], the N-terminal sequence encoding amino
acids 1–120 were fused to the DNA sequence encoding amino acids
570–911. A PCR product encoding the SAP97 N-terminus was
subcloned into the 5′ Xho1 and 3′ EcoRI sites of pEGFP-N2 (Clontech,
Mountain View, CA), and the SH3–GuK PCR product was then
subcloned with the SAP97 N-terminus using the EcoRI/SalI restric-
tion sites in pEGFP-N2. The GuK domain (amino acids 710–911)
was subcloned into the EcoR1/Sal1 site of pEGFP-N2, and the
EcoR1/Sal1 sites in pEGFP-C2. SH3–GuK domains (amino acids
570–911) were subcloned into the EcoR1/Sal1 site in pEGFP-N2.
DNA encoding PDZ1-3 of SAP97 (amino acids 223–554) was
subcloned into the same restriction sites in pEGFP-N2. All chimera
and segment sequences were conﬁrmed by sequencing. The SAP97
SH3 domain (amino acids 572–664) was synthesized and sequenced
by IDT (San Diego, Ca) and subcloned from an IDT vector into the
EcoR1/Sal1 sites of pEGFP-N2.4.6. ELISAs
ELISAs were performed with IL2RA using the 7G7B6 as previously
reported [37]. ELISAswithVE constructs using the I1 antibodywere per-
formed as previously reported with modiﬁcations. COS-1 cells in 10 cm
plateswere transfected overnight, washedwithmedia, and treatedwith
trypsin–EDTA solution (Life Technologies). Cells from transfected plates
were then diluted in media and distributed equally in 6-well dishes.
After 24 h, they were placed at 40 °C for 24 h. Trafﬁcking out of the ER
was initiated by exchanging 40 °C media for 32 °C, and terminated by
either 4% paraformaldehyde in PBS (VE ELISAs) or freezing (enzymatic
treatments and Western blotting). Paired wells were blocked for 1 h
in 10% goat serum in PBS (GPBS; surface), or permeabilized for 5 min
with 2 ml of 0.25% TritonX-100 in GPBS, then blocked in GPBS. Surface
and total wells were then incubated with I1 antibody for 1 h at RT.
Two wells on each plate were not incubated with I1 and used to calcu-
late background. After I1 incubation, wells were washed 3 times with
3 ml PBS for at least 1 min with gentle rocking. Wells were incubated
with HRP-conjugated goat anti-mouse secondary antibody (Jackson
Laboratories) for 30 min, washed 3 times with PBS, and quantiﬁed as
described previously [37].
4.7. Immunoﬂuorescence immunocytochemistry
Immunolabeling was performed in COS-1 cells and Hela cells as
described previously [31,37].
4.8. Confocal microscopy
Cells were imaged using a Zeiss LSM510 scanning confocal micro-
scope (Fig. 2, S1–S2) and a Nikon TE-2000U confocal microscope with
D-Eclipse C1 system (Fig. 2, 3–5). Representative pictures were taken
at 1024 × 1024 pixels with 20×, 63× (1.4 N.A.) or 60× (1.1 N.A.) Plan
Apo oil objectives, or 100× (1.4 N.A.) Plan Apo oil. The signal gain was
varied to achieve approximately matched pixel intensity distributions
across compared images for co-localization. All settings were kept
identical within and across groups to compare average intensities.
4.9. Quantitative image analysis
Images taken for quantiﬁcation of dual-color co-localizationwere all
one optical section of 0.8 μm for each color. Picture acquisition for VE1-3
overlap with GM130 with or without SAP97 was performed blind.
Data collection for quantitative analysis of VE1-3 co-localization with
calnexin was performed similarly, but could not be blinded. Image
analysis was performed using Fiji. LSM and IDS ﬁles were converted to
2- and 3-color TIFF ﬁles. Co-localization was determined for compari-
son by using a Costes threshold and Mander's coefﬁcients for VE1-3
co-localization with GM130, and Rcoloc was used for VE1-3 co-
localization with calnexin (Costes thresholded Pearson's coefﬁcient).
For surface expression of full-length receptors, cells were outlined and
the mean gray values per unit area taken.
4.10. Statistical analysis
Student's t-test or the Mann–Whitney test (Fig. S2A) was used to
determine statistical signiﬁcance (at least p b 0.05) between two
groups. The Mann–Whitney test was performed considering each cell
an independent measure for ranking. When more than 2 groups were
compared, or when repeated-measures were taken into account, a
one-way ANOVA was used, and subsequent pairwise post hoc compari-
sons were made using Tukey's test with a 95% conﬁdence interval.
Statistical tests were performed using Excel.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.11.030.
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